Diabetes Drug's Heart-Protecting secrets remain a mystery as study fails
NCT ID NCT05139914
Summary
This study aimed to understand how the diabetes medication dapagliflozin might improve the health of blood vessels in people with type 2 diabetes, potentially reducing their risk of heart attack and stroke. Researchers planned to compare the drug against a placebo in a small group of participants to see its effects on blood vessel function and related biological markers. However, the study was terminated early because not enough people enrolled to provide meaningful results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BU School of Medicine Evans 748
Boston, Massachusetts, 02118, United States
Conditions
Explore the condition pages connected to this study.